A promising treatment, retatrutide, is creating considerable buzz within the Australian weight management community. Created by the company, this dual GIP and GLP-1 agonist appears to offer more significant outcomes than existing therapies. Initial clinical trials have shown noteworthy diminutions in body mass, suggesting the potential for a differ